Pacira BioSciences (PCRX) Price to Earnings (2011 - 2026)

Pacira BioSciences has reported Price to Earnings for 16 years, with the latest figure at 217.13 in Q2 2026.

• On a quarterly basis, Price to Earnings rose 198.08% year-over-year to 217.13 in Q2 2026; TTM through Jun 2026 was 69.02, a 919.82% increase from a year earlier, with the FY2025 full-year figure at 151.28, up 1828.86% from the prior year.
• Price to Earnings was 217.13 for Q2 2026 at Pacira BioSciences, down from 304.66 in the prior quarter.
• The five-year high for Price to Earnings was 650.03 in Q4 2025, with the low at 3520.24 in Q3 2022.
• Average Price to Earnings over 5 years is 67.96, with a median of 101.68 recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Price to Earnings sank 2593.37% in 2022, then jumped 4310.53% in 2025.
• Over 5 years, Price to Earnings stood at 175.54 in 2022, then surged by 135.92% to 63.06 in 2023, then retreated by 13.88% to 54.31 in 2024, then surged by 1096.91% to 650.03 in 2025, then tumbled by 66.6% to 217.13 in 2026.
• The last three Price to Earnings figures came in at 217.13 (Q2 2026), 304.66 (Q1 2026), and 650.03 (Q4 2025), per Business Quant data.